Company Encyclopedia
View More
name
Avid Bioservices
CDMO.US
Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc.
1.946 T
CDMO.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking0/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-133.29%E
    • Profit Margin-101.07%E
    • Gross Margin-6.11%E
  • Growth ScoreD
    • Revenue YoY6.75%C
    • Net Profit YoY-1143.76%E
    • Total Assets YoY-28.98%E
    • Net Assets YoY-75.56%E
  • Cash ScoreC
    • Cash Flow Margin-98.94%D
    • OCF YoY6.75%C
  • Operating ScoreC
    • Turnover0.39C
  • Debt ScoreE
    • Gearing Ratio86.15%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    19:55 ET Avid Bioservices ernennt Dave Stewart zum Chief Technology and Transformation Officer

    Avid Bioservices, Inc. has appointed Dave Stewart as Chief Technology and Transformation Officer, a newly created position aimed at driving the company's next growth phase. CEO Kenneth Bilenberg emphasized that this role is crucial for positioning Avid as a reliable and proactive external partner. Stewart will lead technology integration and process transformation initiatives, focusing on digital modernization and automation across Avid's development and manufacturing network. This appointment reflects Avid's commitment to continuous improvement and customer partnerships as it expands its capabilities.

    prnewswire·
    US
    CDMO
    0.00%
    prnewswire·
    US
    CDMO
    0.00%

    08:05 ET Avid Bioservices Welcomes Kenneth Bilenberg as new CEO

    Avid Bioservices, Inc. has appointed Kenneth Bilenberg as its new CEO, succeeding Nick Green, who stepped down for health reasons. Bilenberg, with over 20 years of industry experience, previously served as COO of Fujifilm Biotechnologies. The board expressed confidence in Bilenberg's ability to lead Avid into its next chapter, focusing on predictable delivery, supporting biopharma reshoring, and expanding capacity to meet global demand. Avid is recognized for its quality and regulatory track record in biomanufacturing solutions.

    prnewswire·
    US
    CDMO
    0.00%
    prnewswire·
    US
    CDMO
    0.00%

    Avid Bioservices (NASDAQ: CDMO) launches new website aimed at boosting brand awareness with improved functionality.

    Avid Bioservices, Inc., a leading biologics contract development and manufacturing organization traded on NASDAQ under the symbol CDMO, disclosed on February 10, 2025, the introduction of its fresh corporate website. With a focus on enhancing customer experience, the website, accessible at , amalgamates Avid's refined brand narrative and visual elements with enhanced functionality and navigation. The company aims to serve biotechnology and pharmaceutical firms by providing top-notch development and manufacturing services.

    Unusual Whales·
    US
    CDMO
    0.00%
    Unusual Whales·
    US
    CDMO
    0.00%

    Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience | CDMO Stock News

    Avid Bioservices, Inc. (NASDAQ: CDMO) has launched a new corporate website aimed at enhancing brand awareness and improving visitor experience. The revamped site features user-friendly navigation, video interaction, and educational resources, reflecting the company's commitment to exceptional service. CEO Nick Green emphasized the website as a showcase of Avid's expertise and facilities, designed to serve both existing and prospective customers. Avid Bioservices specializes in biologics contract development and manufacturing, offering a range of services for the biotechnology and biopharmaceutical industries.

    StockTitan·
    US
    CDMO
    0.00%
    StockTitan·
    US
    CDMO
    0.00%

    Avid Bioservices Acquired by GHO and Ampersand Capital

    Avid Bioservices has been acquired by GHO Capital and Ampersand Capital Partners for approximately $1.1 billion, leading to its delisting from Nasdaq. This acquisition aims to support Avid's growth and enhance its capabilities in the CDMO sector. Avid Bioservices specializes in the development and manufacturing of biologics, offering a range of services for the biotechnology and biopharmaceutical industries. The merger is expected to accelerate innovation and expand Avid's global market reach, benefiting stakeholders.

    Tip Ranks·
    US
    CDMO
    0.00%
    Tip Ranks·
    US
    CDMO
    0.00%
    © 2025 Longbridge｜Disclaimer